• Dry Cracked Skin
  • Impetigo
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

Final Thoughts on Tapinarof in AD Clinical Trials


Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review the study results for the ADORING 1 and ADORING 2 trials, as well as share closing thoughts on the use of tapinarof in management of AD.

This is a video synopsis/summary of a panel discussion involving Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD.

In summary, the discussion revolves around the positive outcomes observed in the clinical trials, ADORING 1 and ADORING 2 of a nonsteroidal topical therapy for moderate to severe atopic dermatitis. The primary and secondary endpoints, including IGA (immunoglobulin A) clear, EASI (eczema area and severity index) 75 values, and itch endpoints, demonstrated successful outcomes, with IGA points ranging from 45 to 46% and EASI75 values exceeding 50%. The speaker highlights the remarkable rapid onset of activity, particularly within the first 2 weeks, prompting questions about the relationship between AHR (aero hydrocarbon receptor) and cutaneous neurons.

Despite initial skepticism, the speaker acknowledges the trial's success in treating atopic dermatitis with a once-daily application of the topical product, emphasizing its safety and tolerability. Notably, there are no restrictions on treatment duration or application extent, and the therapy is well-balanced for patients as young as 2 years old. The discussion concludes with reflections on the potential paradigm shift in topical therapy, envisioning a future where nonsteroidal treatments, like the 1 discussed, could replace traditional topical steroids. The speakers express excitement about tapinarof’s efficacy across a range of severities, its safety profile, and the possibility of addressing patient needs without significant limitations.

Video synopsis is AI-generated and reviewed by Dermatology Times editorial staff.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.